OpenAI launched ChatGPT for Clinicians on 22 April 2026 — a free version of ChatGPT designed specifically for verified clinicians in the United States, supporting clinical work at the point of care. The product includes trusted clinical search with real-time citations from peer-reviewed sources, deep research across medical literature, reusable workflow skills for documentation tasks, and CME credit support. It is powered by GPT-5.4, which OpenAI says outperforms human physicians on the new HealthBench Professional benchmark.
This is a major signal: the largest AI company in the world now treats clinicians as a distinct professional market requiring purpose-built tools — not just a consumer segment using a general chatbot. The American Medical Association's 2026 survey found 72% of US physicians now use AI in clinical practice, up from 48% just one year earlier.
But ChatGPT for Clinicians is US-only. Verification requires a National Provider Identifier (NPI). OpenAI says it plans to expand internationally over time via the Better Evidence Network, but at launch, UK clinicians cannot access it.
Why the US-Only Detail Matters
Clinical AI is not jurisdiction-neutral. A prescribing answer, referral recommendation, or guideline citation may differ materially between the US and UK. US clinical AI draws from US guidelines (ACC/AHA, ADA, IDSA), US drug labels (FDA-approved), and US clinical workflows (insurance-driven referral, US-specific monitoring protocols). UK clinical AI needs NICE and CKS guideline alignment, SmPC/eMC medicines data approved by the MHRA, UK-specific drug safety alerts, UK referral pathways, and UK professional governance assumptions.
A UK GP asking "what is the first-line treatment for hypertension?" needs the NICE NG136 answer — not the ACC/AHA answer, which recommends different drugs at different thresholds. A UK pharmacist checking a dose adjustment needs the UK-licensed SmPC — not an FDA drug label for a product that may have different licensed indications in the UK. A UK trainee preparing for MRCP needs UK curriculum content — not USMLE-oriented clinical reasoning.
ChatGPT for Clinicians may eventually serve UK clinicians well. But at launch, the source grounding, guideline orientation, and prescribing context are US-centric — because that is the market the product was built for.
What UK Clinicians Need Instead
UK clinical AI should provide: cited answers grounded in UK authoritative sources (NICE, CKS, SmPC/eMC, MHRA), medicines information from UK-regulated product data rather than US drug labels, alignment with UK professional exams (MRCP, MRCGP AKT, PLAB, UKMLA, GPhC CRA), clinical calculators with UK guideline references, CPD documentation aligned with GMC/GPhC revalidation requirements, and professional-facing design that supports — rather than replaces — clinical judgement.
Where iatroX Fits
iatroX is built for clinicians and healthcare professionals who need answers grounded in UK clinical sources. Its clinical AI layer is designed around source-grounded retrieval from curated UK sources, citation-aware synthesis, algorithmic fidelity controls, fail-safe behaviour (narrowing, abstaining, or escalating when confidence is inadequate), and feedback mechanisms allowing clinicians to flag outputs that need review.
The platform combines Ask iatroX for clinical answers, 80+ calculators with guideline references, 15+ adaptive exam Q-banks covering UK and international exams, and CPD for reflective practice. UKCA-marked, MHRA-registered.
For UK clinical questions, use a professional-facing tool built around UK guidance, UK medicines information, and source-verifiable clinical answers.